Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of AL2846 in Advanced Cancer
NCT02779699Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vilzemetkib in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-Limiting Toxicity at 4 weeks, Pharmacokinetics up to 28 Days and 1 more. Status: unknown.
02
Drugs
vilzemetkib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02779699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02779699.